{"id":"recombinant-human-urokinase","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hemorrhage"},{"rate":"5-10%","effect":"Allergic reactions"},{"rate":"null","effect":"Anaphylaxis"}]},"_chembl":{"chemblId":"CHEMBL1201718","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This process is crucial in treating conditions such as pulmonary embolism and ischemic stroke. The drug's mechanism is based on its ability to dissolve blood clots, thereby restoring blood flow to affected areas.","oneSentence":"Recombinant human urokinase is a thrombolytic agent that works by activating plasminogen to plasmin, which then breaks down blood clots.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:38.701Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary embolism"},{"name":"Ischemic stroke"}]},"trialDetails":[{"nctId":"NCT05700591","phase":"PHASE3","title":"rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2023-01-29","conditions":"Acute Ischemic Stroke","enrollment":1552},{"nctId":"NCT04590794","phase":"","title":"SuPAR in Adult Patients With Covid-19","status":"COMPLETED","sponsor":"University of Thessaly","startDate":"2020-10-11","conditions":"Covid19","enrollment":767},{"nctId":"NCT03541668","phase":"PHASE3","title":"Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2018-05-18","conditions":"Acute Ischaemic Stroke","enrollment":674},{"nctId":"NCT03578822","phase":"PHASE3","title":"Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2018-08-10","conditions":"Acute Ischaemic Stroke","enrollment":149}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rhPro-UK"],"phase":"phase_3","status":"active","brandName":"Recombinant human urokinase","genericName":"Recombinant human urokinase","companyName":"Tasly Biopharmaceuticals Co., Ltd.","companyId":"tasly-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant human urokinase is a thrombolytic agent that works by activating plasminogen to plasmin, which then breaks down blood clots. Used for Pulmonary embolism, Ischemic stroke.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}